393 related articles for article (PubMed ID: 30520221)
1. Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centre, randomized, controlled trial.
Gu T; Ma J; Zhang Q; Zhu L; Zhang H; Xu L; Cheng J; Shi B; Li D; Shao J; Sun Z; Zhong S; Bi Y; Zhu D
Diabetes Obes Metab; 2019 Apr; 21(4):939-948. PubMed ID: 30520221
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION).
Schernthaner G; Durán-Garcia S; Hanefeld M; Langslet G; Niskanen L; Östgren CJ; Malvolti E; Hardy E
Diabetes Obes Metab; 2015 Jul; 17(7):630-8. PubMed ID: 25761977
[TBL] [Abstract][Full Text] [Related]
3. Effects of Glimepiride versus Saxagliptin on β-Cell Function and Hypoglycemia: A Post Hoc Analysis in Older Patients with Type 2 Diabetes Inadequately Controlled with Metformin.
Perl S; Cook W; Wei C; Ohman P; Hirshberg B
Clin Ther; 2016 Dec; 38(12):2578-2588. PubMed ID: 27823868
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.
Moses RG; Kalra S; Brook D; Sockler J; Monyak J; Visvanathan J; Montanaro M; Fisher SA
Diabetes Obes Metab; 2014 May; 16(5):443-50. PubMed ID: 24205943
[TBL] [Abstract][Full Text] [Related]
5. Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea.
Xiaoyan C; Jing W; Xiaochun H; Yuyu T; Shunyou D; Yingyu F
Curr Med Res Opin; 2016 Jun; 32(6):1131-6. PubMed ID: 26950829
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes.
Müller-Wieland D; Kellerer M; Cypryk K; Skripova D; Rohwedder K; Johnsson E; Garcia-Sanchez R; Kurlyandskaya R; Sjöström CD; Jacob S; Seufert J; Dronamraju N; Csomós K
Diabetes Obes Metab; 2018 Nov; 20(11):2598-2607. PubMed ID: 29947099
[TBL] [Abstract][Full Text] [Related]
7. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.
Jadzinsky M; Pfützner A; Paz-Pacheco E; Xu Z; Allen E; Chen R;
Diabetes Obes Metab; 2009 Jun; 11(6):611-22. PubMed ID: 19515181
[TBL] [Abstract][Full Text] [Related]
8. Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
Handelsman Y; Mathieu C; Del Prato S; Johnsson E; Kurlyandskaya R; Iqbal N; Garcia-Sanchez R; Rosenstock J
Diabetes Obes Metab; 2019 Apr; 21(4):883-892. PubMed ID: 30499237
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
Lukashevich V; Del Prato S; Araga M; Kothny W
Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial.
Frias JP; Gonzalez-Galvez G; Johnsson E; Maaske J; Testa MA; Simonson DC; Dronamraju N; Garcia-Sanchez R; Peters AL
Diabetes Obes Metab; 2020 Jul; 22(7):1083-1093. PubMed ID: 32052516
[TBL] [Abstract][Full Text] [Related]
11. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
[TBL] [Abstract][Full Text] [Related]
12. Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin.
Rosenstock J; Mathieu C; Chen H; Garcia-Sanchez R; Saraiva GL
Arch Endocrinol Metab; 2018 Aug; 62(4):424-430. PubMed ID: 30304106
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase IV open-label randomized controlled study (the SMART study).
Du J; Liang L; Fang H; Xu F; Li W; Shen L; Wang X; Xu C; Bian F; Mu Y
Diabetes Obes Metab; 2017 Nov; 19(11):1513-1520. PubMed ID: 28296055
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes.
Li CJ; Yu Q; Yu P; Zhang QM; Ding M; Liu XJ; Yu DM
Exp Clin Endocrinol Diabetes; 2014 Sep; 122(8):469-76. PubMed ID: 24838155
[TBL] [Abstract][Full Text] [Related]
15. Vildagliptin more effectively achieves a composite endpoint of HbA₁c < 7.0% without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment.
Bader G; Geransar P; Schweizer A
Diabetes Res Clin Pract; 2013 Jun; 100(3):e78-81. PubMed ID: 23538267
[TBL] [Abstract][Full Text] [Related]
16. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
[TBL] [Abstract][Full Text] [Related]
17. Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.
Sjöstrand M; Iqbal N; Lu J; Hirshberg B
Diabetes Res Clin Pract; 2014 Aug; 105(2):185-91. PubMed ID: 24947443
[TBL] [Abstract][Full Text] [Related]
18. One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin.
Matthaei S; Aggarwal N; Garcia-Hernandez P; Iqbal N; Chen H; Johnsson E; Chin A; Hansen L
Diabetes Obes Metab; 2016 Nov; 18(11):1128-1133. PubMed ID: 27403645
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
Kadowaki T; Kondo K
Diabetes Obes Metab; 2014 May; 16(5):418-25. PubMed ID: 24205974
[TBL] [Abstract][Full Text] [Related]
20. Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes.
Rosenstock J; Gross JL; Aguilar-Salinas C; Hissa M; Berglind N; Ravichandran S; Fleming D
Diabet Med; 2013 Dec; 30(12):1472-6. PubMed ID: 23802840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
